Figure 3
Epstein-Barr virus load in peripheral blood mononuclear cells in the longitudinal study. (a) Epstein-Barr virus (EBV) load between week 0 (W0) and week 12 (W12) for all treated patients (n = 42). (b) EBV-specific IFNγ-producing T cells per 106 peripheral blood mononuclear cells between W0 and W12 for all patients receiving anti-TNF drugs (n = 40). PBMCs, peripheral blood mononuclear cells.
